US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by ProLynx Inc.

News headline image
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
From ProLynx Inc.
Via GlobeNewswire
Tickers CLLS MGX
News headline image
Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer
From ProLynx Inc.
Via GlobeNewswire
News headline image
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
From ProLynx Inc.
Via GlobeNewswire
News headline image
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
From ProLynx Inc.
Via GlobeNewswire
News headline image
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
From ProLynx Inc.
Via GlobeNewswire